PET Radionuclides in the prognosis and diagnosis of Glioma

Background: Early diagnosis of glioma have an important role in management of treatment. PET provides additional insight beyond MRI into the biology of gliomas which can be used for noninvasive grading, tumor infiltration, post-treatment monitoring and prognostication. In this study, the performance of commonly used Radionuclides for glioma imaging with PET is surveyed and compared.Materials and Methods: In this study, published articles with the keywords PET radionuclide , glioma were searched from the scientific databases and then the results were analysisResults: Currently, the most important commercial radiopharmaceuticals used in PET imaging are in two categories: Radionuclides of glucose synthesis such as fluorodeoxyglucose (FDG), and amino acid based Radionuclides, including: Fluoroethyl L Thymidine (FLT), methyl methionine carbonate (C-MET), Fluoroethylthirosine (FET) and dihydroxy fluoro-L-phenylalanine (FDOPA). FDG radiopharmaceuticals is not suitable for intracranial imaging, the sensitivity and specificity reorted 53% and 55 % respectively. Amino acid based Radionuclides have less uptake than FDG in the normal brain tissue. FLT is strongly correlated with Ki67 proliferation biomarker. Its sensitivity is 91% in all glioma grades and for grade 3, 4 it is about 100%. Sensitivity of FET, MET and FDOPA are similar and about 95%, but there have a high False Positive cases because of the uptake in fractures, infections and hemorrhage.Conclusion: FLT is recommended as a specific radiotracer in glioma. There is not still appropriate technique for identification of the PET active volumes, so it seems PET cannot be yet replaced by MRI.

کلیدواژه ها:

Glioma ، PET imaging ، PET Radionuclide